The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Domzalski David since 2018.
The trader's CIK number is 1727794.
At the time of the last reporting, Domzalski David was the President and CEO of Vyne Therapeutics Inc.. (stock ticker symbol VYNE).
Also see all insider trading activities at Vyne Therapeutics Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2020 | VYNE | 75,000 | $103,575 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2019 | FOMX | 0 | $0 | 8,451 | $26,994 | 0 | $0 |
| 2018 | FOMX | 0 | $0 | 17,409 | $86,891 | 5,948 | $0 |
1. Vyne Therapeutics Inc. (VYNE)
2. Foamix Pharmaceuticals Ltd. (FOMX)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2020-09-08 | VYNE | Buy | 75,000 | 1.38 | 103,575 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2019-07-01 | FOMX | Sale | 3,355 | 2.35 | 7,884 |
| 2019-04-01 | FOMX | Sale | 5,096 | 3.75 | 19,110 |
| 2018-12-03 | FOMX | Sale | 68 | 4.05 | 275 |
| 2018-11-19 | FOMX | Sale | 5,036 | 3.90 | 19,640 |
| 2018-11-08 | FOMX | Sale | 2,062 | 4.58 | 9,443 |
| 2018-10-01 | FOMX | Sale | 601 | 5.81 | 3,491 |
| 2018-09-04 | FOMX | Sale | 67 | 5.67 | 379 |
| 2018-08-08 | FOMX | Sale | 8,238 | 5.68 | 46,791 |
| 2018-07-02 | FOMX | Sale | 602 | 5.10 | 3,070 |
| 2018-06-01 | FOMX | Sale | 67 | 5.26 | 352 |
| 2018-04-02 | FOMX | Sale | 602 | 5.08 | 3,058 |
| 2018-03-01 | FOMX | Sale | 66 | 5.95 | 392 |
| 2018-01-01 | FOMX | Option Ex | 5,948 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Domzalski David (President and CEO of Vyne Therapeutics Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.